Randomized Controlled Trial of Acetazolamide Added to Antipsychotics for Treatment Resistant Schizophrenia in Adults 18-55

What this Trial Is About

Researchers are evaluating acetazolamide as an additional treatment for people with treatment-resistant schizophrenia and schizoaffective disorder. This double-blind randomized controlled trial aims to find out if adding acetazolamide to current antipsychotic drugs can improve symptoms, including positive and negative symptoms, cognitive function, social functioning, and quality of life. Schizophrenia is a serious condition with limited treatment options, and acetazolamide has been identified as a potential repurposed drug due to its effects on brain carbonic anhydrase. Participants will receive either acetazolamide capsules starting at 250 mg per day, gradually increased over 7 to 10 days to 2 grams per day, or placebo capsules identical in appearance. The study uses a crossover design where participants receive both treatments in sequence, each for 8 weeks, added to their stable antipsychotic medications. This approach maximizes the studys power to detect differences while monitoring safety and tolerability. During the 24-week study period, participants will be regularly assessed for changes in positive symptoms, clinical severity, cognition, social function, overall functioning, quality of life, socio-economic status, and side effects. The study involves thorough monitoring, including symptom rating scales and evaluations of satisfaction with life. The total participation time includes treatment phases and follow-up to capture treatment effects and safety outcomes.

Acetazolamide for Treatment Resistant Schizophrenia